Cover Image

BRAF inhibition in refractory hairy-cell leukemia

Show other versions (1)

To the Editor: Hairy-cell leukemia (HCL) is a mature B-cell lymphoid cancer that is commonly treated with purine analogues.1 Virtually all patients with HCL carry the BRAF V600E mutation, which constitutively activates the MEK-ERK pathway and which can be inhibited in vitro by the mutation-specific...

Full description

Saved in:
Bibliographic Details
Main Authors: Dietrich, Sascha (Author) , Glimm, Hanno (Author) , Andrulis, Mindaugas (Author) , Kalle, Christof von (Author) , Ho, Anthony Dick (Author) , Zenz, Thorsten (Author)
Format: Article (Journal)
Language:English
Published: May 24, 2012
In: The New England journal of medicine
Year: 2012, Volume: 366, Issue: 21, Pages: 2038-2040
ISSN:1533-4406
DOI:10.1056/NEJMc1202124
Online Access:Verlag, Volltext: http://dx.doi.org/10.1056/NEJMc1202124
Verlag, Volltext: https://doi.org/10.1056/NEJMc1202124
Get full text
Author Notes:Sascha Dietrich, Hanno Glimm, Mindaugas Andrulis, Christof von Kalle, Anthony D. Ho, Thorsten Zenz
Search Result 1
Cover Image

BRAF inhibition in refractory hairy-cell leukemia by Dietrich, Sascha (Author) , Glimm, Hanno (Author) , Andrulis, Mindaugas (Author) , Kalle, Christof von (Author) , Ho, Anthony Dick (Author) , Zenz, Thorsten (Author) ,


Get full text
Article (Journal)

Saved in:
Show all versions (2)

Similar Items